Reports engineering of a dual-deleted vaccinia virus that delivers a tumor‑selective neutrophil protease to enhance oncolytic and immune responses in tumors.
Key Takeaways
- Broad-spectrum anticancer therapies are challenging due to the spatial and temporal tumor heterogeneity ( 1 )
- Serum-free conditioned media from human PMNs displayed tumor-selective cytotoxicity
- Functional studies revealed that human neutrophil elastase (ELANE)